ATE370941T1 - Modulatoren des vitamin-d-rezeptors - Google Patents

Modulatoren des vitamin-d-rezeptors

Info

Publication number
ATE370941T1
ATE370941T1 AT04819516T AT04819516T ATE370941T1 AT E370941 T1 ATE370941 T1 AT E370941T1 AT 04819516 T AT04819516 T AT 04819516T AT 04819516 T AT04819516 T AT 04819516T AT E370941 T1 ATE370941 T1 AT E370941T1
Authority
AT
Austria
Prior art keywords
vitamin
receptor
modulators
compounds
secosteroidal
Prior art date
Application number
AT04819516T
Other languages
English (en)
Inventor
Jianliang Lu
Tainwei Ma
Sunil Nagpal
Quanrong Shen
Alan Warshawsky
Ying Yee
Michael Rupp
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE370941T1 publication Critical patent/ATE370941T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04819516T 2003-11-20 2004-11-16 Modulatoren des vitamin-d-rezeptors ATE370941T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52360003P 2003-11-20 2003-11-20

Publications (1)

Publication Number Publication Date
ATE370941T1 true ATE370941T1 (de) 2007-09-15

Family

ID=34632799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819516T ATE370941T1 (de) 2003-11-20 2004-11-16 Modulatoren des vitamin-d-rezeptors

Country Status (8)

Country Link
US (2) US7582775B2 (de)
EP (1) EP1687292B1 (de)
JP (1) JP4717006B2 (de)
AT (1) ATE370941T1 (de)
CA (1) CA2544522A1 (de)
DE (1) DE602004008505T2 (de)
ES (1) ES2291981T3 (de)
WO (1) WO2005051940A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184281A1 (de) * 2002-05-29 2010-05-12 Eli Lilly & Company Vitamin-D-Rezeptormodulatoren vom Phenyl-Thiophen-Typ
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
CA2544517A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
US7595345B2 (en) 2003-11-20 2009-09-29 Eli Lilly And Company Vitamin D receptor modulators
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005051938A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
ES2307069T3 (es) 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
EP1771413B1 (de) * 2004-05-03 2011-09-21 Janssen Pharmaceutica NV Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
KR100931777B1 (ko) * 2004-12-21 2009-12-14 일라이 릴리 앤드 캄파니 비타민 ｄ 수용체 조절제
WO2006069153A2 (en) * 2004-12-21 2006-06-29 Eli Lilly And Company Vitamin d receptor modulators
EP1676834A1 (de) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Kondensierte Bicyclische Carboxamid-Derivate zur Verwendung als CXCR2 Inhibitoren zur Behandlung von Entzündungen
EP2040690B1 (de) 2006-06-28 2014-08-06 Sanofi Cxcr2-inhibitoren
JP5352454B2 (ja) 2006-06-28 2013-11-27 サノフイ Ｃｘｃｒ２アンンタゴニスト
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.
JP5352455B2 (ja) 2006-06-30 2013-11-27 サノフイ Ｃｘｃｒ２阻害剤
US10100015B2 (en) * 2015-03-24 2018-10-16 Shanghai Yingli Pharmaceutical Co., Ltd. Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1137733B (de) * 1954-06-05 1962-10-11 Chem Fab Promonta G M B H Verfahren zur Herstellung von Aryl- und Thienylmethylphenylalkylaminen
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
DE19718334A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2002508383A (ja) * 1997-12-17 2002-03-19 シエーリング アクチエンゲゼルシャフト 側鎖中にリン原子を有するビタミンｄ誘導体
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
FR2801307B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
EP2184281A1 (de) * 2002-05-29 2010-05-12 Eli Lilly & Company Vitamin-D-Rezeptormodulatoren vom Phenyl-Thiophen-Typ
BR0316401A (pt) 2002-11-22 2006-02-21 Lilly Co Eli composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto
WO2004063345A2 (en) 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
EP1587905A3 (de) 2003-01-10 2005-12-14 Eli Lilly And Company Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-thiophen-typs
WO2005037755A2 (en) * 2003-10-14 2005-04-28 X-Ceptor Therapeutics, Inc. Bridged ring structures as pharmaceutical agents
ES2307069T3 (es) 2003-11-20 2008-11-16 Eli Lilly And Company Compuestos de fenilfurano como moduladores del receptor de la vitamina d.
US7595345B2 (en) 2003-11-20 2009-09-29 Eli Lilly And Company Vitamin D receptor modulators
CA2544517A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005051938A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
KR100931777B1 (ko) 2004-12-21 2009-12-14 일라이 릴리 앤드 캄파니 비타민 ｄ 수용체 조절제
WO2006069153A2 (en) 2004-12-21 2006-06-29 Eli Lilly And Company Vitamin d receptor modulators

Also Published As

Publication number Publication date
US20100076065A1 (en) 2010-03-25
US7582775B2 (en) 2009-09-01
ES2291981T3 (es) 2008-03-01
EP1687292B1 (de) 2007-08-22
DE602004008505D1 (de) 2007-10-04
DE602004008505T2 (de) 2008-05-21
WO2005051940A3 (en) 2005-08-11
US7897789B2 (en) 2011-03-01
WO2005051940A2 (en) 2005-06-09
US20070149810A1 (en) 2007-06-28
JP2007512329A (ja) 2007-05-17
EP1687292A2 (de) 2006-08-09
JP4717006B2 (ja) 2011-07-06
CA2544522A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CY1108988T1 (el) Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el) Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
ATE370941T1 (de) Modulatoren des vitamin-d-rezeptors
WO2005051893A3 (en) Vitamin d receptor modulators
ATE396982T1 (de) Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
DE69911596D1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
PA8493701A1 (es) Compuestos para tratar la obesidad
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
WO2005051898A3 (en) Vitamin d receptor modulators
AU2003233735A8 (en) 24-sulfoximine vitamin d3 compounds
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
ATE165819T1 (de) 26,28-methylen-1alpha,25-dihydroxy-vitamin-d2- verbindungen
IL168147A (en) Substituted tetralins and indanes and their use
DE60326272D1 (de) Komponenten des ampk-wegs
ATE455749T1 (de) Verbindungen mit verbrückten ringen als pharmazeutische mittel
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
ATE509269T1 (de) Verfahren und verbindungen zur modulierung von apoptosis
NO20052199L (no) Substituerte tetraliner og indaner
ATE417035T1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen
WO2003105854A3 (en) CALCIUM CHANNEL INHIBITORS BASED ON DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND SUBSTITUTED DIHYDROPYRIMIDINETHIONES

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties